DK3150256T3 - Kombination af anti-cd20-antistof og pi3-kinaseselektiv hæmmer - Google Patents

Kombination af anti-cd20-antistof og pi3-kinaseselektiv hæmmer Download PDF

Info

Publication number
DK3150256T3
DK3150256T3 DK16185090.4T DK16185090T DK3150256T3 DK 3150256 T3 DK3150256 T3 DK 3150256T3 DK 16185090 T DK16185090 T DK 16185090T DK 3150256 T3 DK3150256 T3 DK 3150256T3
Authority
DK
Denmark
Prior art keywords
antibody
chinese
combination
selective inhibitor
inhibitor
Prior art date
Application number
DK16185090.4T
Other languages
Danish (da)
English (en)
Inventor
Swaroop K V S Vakkalanka
Michael Weiss
Hari Miskin
Peter Sportelli
Original Assignee
Tg Therapeutics Inc
Rhizen Pharmaceuticals Sa
Lab Francais Du Fractionnement
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54264181&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3150256(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Tg Therapeutics Inc, Rhizen Pharmaceuticals Sa, Lab Francais Du Fractionnement filed Critical Tg Therapeutics Inc
Application granted granted Critical
Publication of DK3150256T3 publication Critical patent/DK3150256T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DK16185090.4T 2012-11-02 2013-11-01 Kombination af anti-cd20-antistof og pi3-kinaseselektiv hæmmer DK3150256T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN4595CH2012 2012-11-02
US201361771812P 2013-03-02 2013-03-02
EP13792152.4A EP2914343B1 (en) 2012-11-02 2013-11-01 Combination of anti-cd20 antibody and pi3 kinase selective inhibitor

Publications (1)

Publication Number Publication Date
DK3150256T3 true DK3150256T3 (da) 2020-08-24

Family

ID=54264181

Family Applications (1)

Application Number Title Priority Date Filing Date
DK16185090.4T DK3150256T3 (da) 2012-11-02 2013-11-01 Kombination af anti-cd20-antistof og pi3-kinaseselektiv hæmmer

Country Status (22)

Country Link
US (3) US9694071B2 (https=)
EP (3) EP3756686A1 (https=)
JP (1) JP6437441B2 (https=)
KR (2) KR102185175B1 (https=)
CN (2) CN110269941A (https=)
AU (3) AU2013337733B2 (https=)
BR (1) BR112015009879A8 (https=)
CA (1) CA2890176C (https=)
CL (1) CL2015001124A1 (https=)
CY (1) CY1123938T1 (https=)
DK (1) DK3150256T3 (https=)
EA (1) EA030745B1 (https=)
IL (1) IL238564B (https=)
LT (1) LT3150256T (https=)
MX (2) MX375325B (https=)
NZ (1) NZ708249A (https=)
PL (1) PL3150256T3 (https=)
RS (1) RS60844B1 (https=)
SG (2) SG11201503393SA (https=)
SI (1) SI3150256T1 (https=)
SM (1) SMT202000543T1 (https=)
WO (1) WO2014071125A1 (https=)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
MX2010007419A (es) 2008-01-04 2010-11-12 Intellikine Inc Ciertas entidades quimicas, composiciones y metodos.
ES2637113T3 (es) 2011-01-10 2017-10-10 Infinity Pharmaceuticals, Inc. Procedimientos para preparar isoquinolinonas y formas sólidas de isoquinolinonas
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
AU2013337717B2 (en) 2012-11-01 2018-10-25 Infinity Pharmaceuticals, Inc. Treatment of cancers using PI3 kinase isoform modulators
US20150320754A1 (en) 2014-04-16 2015-11-12 Infinity Pharmaceuticals, Inc. Combination therapies
WO2015160975A2 (en) 2014-04-16 2015-10-22 Infinity Pharmaceuticals, Inc. Combination therapies
WO2016004221A1 (en) * 2014-07-01 2016-01-07 Mayo Foundation For Medical Education And Research Methods and materials for identifying and treating mammals resistant to proteasome inhibitor treatments
JP7065782B2 (ja) 2016-03-18 2022-05-12 フレッド ハッチンソン キャンサー リサーチ センター Ｃｄ２０免疫療法のための組成物および方法
EP3463318A4 (en) * 2016-05-27 2020-01-01 TG Therapeutics Inc. COMBINATION OF ANTI-CD20-ANTIBODIES, P13-KINASE-DELTA-SELECTIVE INHIBITOR AND BTK-INHIBITOR FOR THE TREATMENT OF PROLIFERATIVE B-CELL DISORDERS
SG11201811237WA (en) 2016-06-24 2019-01-30 Infinity Pharmaceuticals Inc Combination therapies
WO2018049263A1 (en) * 2016-09-09 2018-03-15 Tg Therapeutics, Inc. Combination of an anti-cd20 antibody, pi3 kinase-delta inhibitor, and anti-pd-1 or anti-pd-l1 antibody for treating hematological cancers
WO2018106945A1 (en) 2016-12-07 2018-06-14 Progenity Inc. Gastrointestinal tract detection methods, devices and systems
WO2018183929A1 (en) 2017-03-30 2018-10-04 Progenity Inc. Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device
KR20200041358A (ko) * 2017-08-14 2020-04-21 메이 파마, 아이엔씨. 병용 요법
WO2019246312A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunomodulator
WO2019246317A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease or condition in a tissue originating from the endoderm
EP3883635A1 (en) 2018-11-19 2021-09-29 Progenity, Inc. Methods and devices for treating a disease with biotherapeutics
CN115666704B (zh) 2019-12-13 2025-09-26 比特比德科有限责任公司 用于将治疗剂递送至胃肠道的可摄取装置
WO2021164789A1 (zh) * 2020-02-21 2021-08-26 南京明德新药研发有限公司 一种吡唑并嘧啶类化合物的晶型及其应用
CN114891005B (zh) * 2022-03-30 2024-01-19 武汉九州钰民医药科技有限公司 一种乌帕利斯对甲苯磺酸盐的制备工艺
US11884740B1 (en) 2022-06-01 2024-01-30 Tg Therapeutics, Inc. Anti-CD20 antibody compositions
US11814439B1 (en) * 2022-06-01 2023-11-14 Tg Therapeutics, Inc. Anti-CD20 antibody compositions
US11965032B1 (en) 2022-06-01 2024-04-23 Tg Therapeutics, Inc. Anti-CD20 antibody compositions
KR20250039512A (ko) * 2022-06-01 2025-03-20 티지 쎄라퓨틱스, 인코포레이티드 항-cd20 항체 조성물
US11807689B1 (en) * 2022-06-01 2023-11-07 Tg Therapeutics, Inc. Anti-CD20 antibody compositions
WO2025174079A1 (ko) * 2024-02-13 2025-08-21 연세대학교 산학협력단 항-cd20 항체 및 pikfyve의 억제제를 유효성분으로 포함하는 림프종의 예방 또는 치료용 조성물

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
WO1999004705A1 (en) 1997-07-25 1999-02-04 Tsui Ban C H Devices, systems and methods for determining proper placement of epidural catheters
FR2807767B1 (fr) 2000-04-12 2005-01-14 Lab Francais Du Fractionnement Anticorps monoclonaux anti-d
FR2844455B1 (fr) 2002-09-13 2007-12-14 Lab Francais Du Fractionnement Traitement des pathologies echappant a la reponse immune par des anticorps optimises
TWI335821B (en) 2002-12-16 2011-01-11 Genentech Inc Immunoglobulin variants and uses thereof
FR2858235B1 (fr) 2003-07-31 2006-02-17 Lab Francais Du Fractionnement Utilisation d'anticorps optimises en adcc pour traiter les patients faibles repondeurs
FR2879204B1 (fr) 2004-12-15 2007-02-16 Lab Francais Du Fractionnement Anticorps cytotoxique dirige contre les proliferations hematopoietiques lymphoides de type b.
JPWO2007102200A1 (ja) * 2006-03-07 2009-07-23 国立大学法人大阪大学 抗ｃｄ２０モノクローナル抗体
AR064106A1 (es) * 2006-12-05 2009-03-11 Bayer Schering Pharma Ag Derivados de 2,3-dihidroimidazo [1,2-c] quinazolina sustituida utiles para el tratamiento de enfermedades y trastornos hiper-proliferativos asociados con la angiogenesis
FR2915398B1 (fr) * 2007-04-25 2012-12-28 Lab Francais Du Fractionnement "ensemble de moyens pour le traitement d'une pathologie maligne, d'une maladie auto-immune ou d'une maladie infectieuse"
WO2010014595A2 (en) * 2008-07-31 2010-02-04 The Ohio State University Research Foundation Methods and compositions for delivering therapeutic agents in the treatment of b-cell related disorders
FR2939314A1 (fr) * 2008-12-04 2010-06-11 Univ Victor Segalen Bordeaux 2 Nouvelles compositions et methodes pour la potentialisation des signaux d'apoptose dans les cellules tumorales
JP5709766B2 (ja) * 2009-03-12 2015-04-30 ジェネンテック， インコーポレイテッド 造血器腫瘍の治療のためのホスホイノシチド３キナーゼ阻害剤化合物と化学療法剤の併用
NZ599830A (en) 2009-11-05 2014-08-29 Rhizen Pharmaceuticals Sa Novel kinase modulators
RS56494B1 (sr) * 2012-07-04 2018-01-31 Rhizen Pharmaceuticals S A Selektivni inhibitori pi3k delta

Also Published As

Publication number Publication date
EA201590866A1 (ru) 2015-12-30
US20150290317A1 (en) 2015-10-15
US10729768B2 (en) 2020-08-04
AU2013337733B2 (en) 2018-03-08
CN110269941A (zh) 2019-09-24
BR112015009879A8 (pt) 2019-09-17
KR102185175B1 (ko) 2020-12-02
RS60844B1 (sr) 2020-10-30
SG11201503393SA (en) 2015-06-29
US20170304441A1 (en) 2017-10-26
CY1123938T1 (el) 2022-03-24
IL238564B (en) 2020-11-30
US20200323981A1 (en) 2020-10-15
LT3150256T (lt) 2020-11-10
AU2018203579A1 (en) 2018-06-14
SG10201704511RA (en) 2017-07-28
JP6437441B2 (ja) 2018-12-12
CN105073197A (zh) 2015-11-18
AU2013337733A1 (en) 2015-06-04
CA2890176C (en) 2021-12-14
EA030745B1 (ru) 2018-09-28
NZ708249A (en) 2019-03-29
EP3756686A1 (en) 2020-12-30
SMT202000543T1 (it) 2020-11-10
AU2020203417A1 (en) 2020-06-11
CN105073197B (zh) 2019-06-28
SI3150256T1 (sl) 2021-03-31
IL238564A0 (en) 2015-06-30
EP3150256B1 (en) 2020-07-15
AU2018203579B2 (en) 2020-02-27
MX2020009919A (es) 2020-10-14
EP3150256A1 (en) 2017-04-05
JP2016505515A (ja) 2016-02-25
US9694071B2 (en) 2017-07-04
BR112015009879A2 (https=) 2014-05-08
CL2015001124A1 (es) 2016-01-08
KR20200136498A (ko) 2020-12-07
KR102341275B1 (ko) 2021-12-21
EP2914343A1 (en) 2015-09-09
EP2914343B1 (en) 2019-03-06
WO2014071125A1 (en) 2014-05-08
MX2015005555A (es) 2015-11-30
MX375325B (es) 2025-03-06
KR20150084885A (ko) 2015-07-22
PL3150256T3 (pl) 2021-02-08
CA2890176A1 (en) 2014-05-08

Similar Documents

Publication Publication Date Title
DK3150256T3 (da) Kombination af anti-cd20-antistof og pi3-kinaseselektiv hæmmer
IL285780A (en) Tmprss6 irna compositions and methods of use thereof
IL267681B (en) Selective grp94 inhibitors and uses thereof
DK3381943T3 (da) Anti-kit-antistoffer og anvendelser deraf
DK3003039T3 (da) Methyl/fluor-pyridinyl-metoxy-substituerede pyridinon-pyridinyl-forbindelser og fluor-pyrimidinyl-metoxy-substituerede pyridinon-pyridinyl-forbindelser
IL227465B (en) Blockstent device amd methods of use
DK3057586T3 (da) Bromodomæneinhibitorer
CO7071096A2 (es) Anticuerpos anti-lgr5 e inmunoconjugados
PL3406633T3 (pl) Przeciwciała wieloswoiste, aktywowalne przeciwciała wieloswoiste i metody ich stosowania
EP2723766A4 (en) COAGONISTS OF GLUCAGON / GLP-1 RECEPTOR
EP2723367A4 (en) Glucagon/glp-1 receptor co-agonists
DK3683235T3 (da) Anti-IL-33-antistoffer og anvendelser deraf
DK3026062T3 (da) Anti-pd-1-antistof og anvendelse deraf
BR112015002193A2 (pt) anticorpos anti-etbr e imunoconjugados
DK2668210T3 (da) Anti-kit antistoffer og anvendelser deraf
DK2914627T3 (da) Anti-cd40-antistoffer og fremgangsmåder til anvendelse
EP2948519A4 (en) DELAYED GELER
DK3086807T3 (da) Antistoffer og fremgangsmåder til anvendelse
HRP20181457T1 (hr) Anti-htra1 protutijela i postupci uporabe
IL238227A0 (en) Anti-c16orf54 antibodies and methods of use thereof
DK2981541T3 (da) Syntese og anvendelse af isotopmærkede glycaner
EP3045047A4 (en) EMULSIFIED COMPOSITION AND MILK DRINK
DK3029038T3 (da) Tetrazolinonforbindelse og anvendelse deraf
PL3042669T3 (pl) Środek przeciwnowotworowy i środek wzmacniający efekt przeciwnowotworowy
DK2951208T3 (da) Anti-cd83 antistoffer og anvendelse deraf